Abstract Library

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#3759 Long-term outcomes of surgical valve replacement in patients with severe carcinoid heart disease

Introduction: Carcinoid Heart Disease (CHD) is a complex complication of carcinoid syndrome (CS), with Surgical Valve Replacement (SVR) being its established treatment in selected patients.

Conference:

Presenting Author: Hayes A

Authors: Matti J, Crompton J, Furtado O'Mahony L, Hayes A, Harrison T,

Keywords: Carcinoid Heart Disease, Valve Replacement, Carcinoid Syndrome, Overall Survival,

#3328 Role of neoadjuvant PRRT in resectable/borderline resectable PanNETs: Clinical, pathological and genomic features

Introduction: The role of preoperative therapies to obtain cytoreduction, especially PRRT, is unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Fumagalli A

Authors: Fumagalli A, Pellicciari M, Reni A, Borghesani M, Zaninotto E,

Keywords: net, prrt, neuroendocrine tumor, pancreas, genomic, neoadjuvant treatment,

#2740 Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report

Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Della Torre S

Authors: Lombardi P, Grandi S, Marinelli M, Manara M, Della Torre S,

Keywords: rectal nec, net, chemotherapy, metastatic disease,

#1722 New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome associated with an increased risk of developing parathyroid, pituitary and pancreatic neuroendocrine tumors. MEN1 has an autosomal dominant pattern of hereditability and it is usually related to mutations in menin coding gene

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Grego E, Pellicciari M, Novak L, Ortolani S, Antista M,

Keywords: MEN1 syndrome, MEN1 gene mutation, neuroendocrine tumor,